Invention Grant
- Patent Title: Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
-
Application No.: US15123195Application Date: 2015-03-04
-
Publication No.: US10040867B2Publication Date: 2018-08-07
- Inventor: James E. Hansen , Richard H. Weisbart , Melissa Young , Philip W. Noble
- Applicant: Yale University , The United States of America as represented by The Department of Veterans Affairs
- Applicant Address: US CT New Haven US DC Washington
- Assignee: Yale University,The United States of America, as Represented by The Department of Veterans Affairs
- Current Assignee: Yale University,The United States of America, as Represented by The Department of Veterans Affairs
- Current Assignee Address: US CT New Haven US DC Washington
- Agency: Pabst Patent Group LLP
- International Application: PCT/US2015/018729 WO 20150304
- International Announcement: WO2015/134607 WO 20150911
- Main IPC: C07K16/40
- IPC: C07K16/40 ; C07K16/30 ; C07K16/44 ; A61K39/395 ; A61K45/06
Abstract:
It has been established that cancer cells with oncogenic mutants in the small GTPase K-Ras are susceptible to antibodies that bind intracellular guanosine, but delivery of antibodies into cells can be challenging. A subset of lupus autoantibodies is associated with anti-guanosine activity, and is capable of cellular penetration. These antibodies have potential as therapeutic agents targeted towards K-Ras associated malignancies.
Public/Granted literature
- US20170073429A1 CELL PENETRATING ANTI-GUANOSINE ANTIBODY BASED THERAPY FOR CANCERS WITH RAS MUTATIONS Public/Granted day:2017-03-16
Information query
